Escherichia (e.g., Escherichia Coli, Etc.) Patents (Class 424/241.1)
  • Patent number: 10335477
    Abstract: The invention provides compositions and methods for preventing, treating and diagnosing infection by Salmonella enterica serovar typhi (S. typhi) and/or S. paratyphi, i.e., typhoid fever.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: July 2, 2019
    Assignee: YALE UNIVERSITY
    Inventors: Jorge E. Galan, Jeongmin Song
  • Patent number: 9095539
    Abstract: The invention relates to an immunogenic composition and method of the immunogenic composition for the production and administration of a passive immunoprophylactic against enterotoxigenic Escherichia coli. The immunoprophylactic is made collecting anti-adhesin in the colostrum or milk of vaccinated domesticated animals such as cows. The immunoprophylactic is administered either as a dietary supplement or in capsular or tablet form.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: August 4, 2015
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Stephen J. Savarino
  • Patent number: 8992940
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: March 31, 2015
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Patent number: 8980279
    Abstract: The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: March 17, 2015
    Assignee: Qu Biologics
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Patent number: 8945587
    Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure relates to genetic engineering of Gram-negative bacteria expressing different species of lipid A on their surface. In one embodiment, the present disclosure provides for an engineered strain of E. coli according to Table 1. In another embodiment, the present disclosure provides for a lipopolysaccharide purified from an engineered strain of E. coli according to Table 1.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 3, 2015
    Assignee: The Board of Regents of The University of Texas System
    Inventors: M. Stephen Trent, Brittany Needham, David Giles, Marvin Whiteley
  • Patent number: 8926992
    Abstract: The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: January 6, 2015
    Assignees: Novartis AG, Universiteit Leiden
    Inventors: Giuseppe Del Guidice, Barbara Baudner
  • Patent number: 8920814
    Abstract: The invention provides compositions and methods for preventing a metabolic disorder or bacterial infection in a subject, the composition comprising a bacterial endotoxin.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: December 30, 2014
    Assignee: The Governors of the University of Alberta
    Inventor: Burim N. Ametaj
  • Publication number: 20140322274
    Abstract: A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 30, 2014
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • Patent number: 8858930
    Abstract: The invention provides live, attenuated enterohemorrhagic Escherichia coli (EHEC) bacteria in which the Shiga toxin coding sequences are deleted to abolish Shiga toxin production and one or more of the nucleotide sequences for the bacterial adhesin protein intimin, the locus of enterocyte effacement encoded regulator, and the translocated intimin receptor are mutated to inactivate the activity of the encoded protein(s). This live, attenuated E. coli bacteria is used in a vaccine for reducing or inhibiting carriage and shedding of EHEC in cattle.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: October 14, 2014
    Assignees: The United States of America as Represented by the Department of Veteran Affairs
    Inventors: Chengru Zhu, Edgar Boedeker
  • Patent number: 8846052
    Abstract: A bacterial toxin protein such as a Shiga toxin protein is efficiently produced using plant cells. The plant cells are transformed using a DNA construct containing DNA encoding a hybrid protein in which the bacterial toxin proteins such as the Shiga toxin proteins are tandemly linked through a peptide having the following characteristics (A) and (B) to produce the bacterial toxin protein in the plant cells: (A) a number of amino acids is 12 to 30; and (B) a content of proline is 20 to 35%.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: September 30, 2014
    Assignees: Idemitsu Kosan Co., Ltd., National University Corporation Nara Institute of Science and Technology
    Inventors: Kazutoshi Sawada, Takeshi Matsui, Mayumi Yoshida, Nobuo Yoshida, Kyoko Yoshida
  • Patent number: 8846058
    Abstract: A chimeric Shiga toxoid according to the invention contains an enzymatically-inactivated StxA subunit and a native StxB subunit. This hybrid Shiga toxoid induces the production of broadly cross-reactive species of antibodies against Shiga toxin following immunization. The StxA subunit is modified so that it is enzymatically inactive. The invention thus encompasses the Shiga toxoid or fragments thereof and the nucleic acid sequence of the Shiga toxoid or fragments thereof. The invention further encompasses the production of a Shiga toxoid, the production of antibodies using the Shiga toxoid and methods of productions, and an immunogenic composition containing the Shiga toxoid.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: September 30, 2014
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Michael J. Smith, Alison D. O'Brien, Louise D. Teel, Angela R. Melton-Celsa
  • Patent number: 8815251
    Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: August 26, 2014
    Assignee: Allertein Therapeutics, LLC
    Inventors: Michael J. Caplan, Howard B. Sosin, H. Kim Bottomly, A. Wesley Burks, Jr., Hugh A. Sampson
  • Patent number: 8734811
    Abstract: Compositions and methods for stimulating an immune response against Shiga toxin-producing Escherichia coli (STEC) antigens are disclosed. The compositions include a multiple epitope fusion protein comprising more than one epitope of an immunogenic STEC protein from more than one STEC serotype. Additional compositions include at least two purified STEC proteins, wherein the STEC proteins are selected from a full-length STEC protein, an immunogenic fragment or variant thereof, wherein at least one of the STEC proteins generates antibodies that react with STEC O157 and at least one other STEC serotype.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: May 27, 2014
    Assignee: University of Saskatchewan
    Inventors: Andrew Potter, David Asper, Dragan Rogan
  • Patent number: 8673311
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 18, 2014
    Assignee: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Publication number: 20140004178
    Abstract: The present disclosure relates to vaccine compositions and methods of using the vaccine compositions to provide protection against various Gram-negative bacterial infections, including Burkholderia infections.
    Type: Application
    Filed: January 12, 2012
    Publication date: January 2, 2014
    Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventor: Lisa A. Morici
  • Patent number: 8481026
    Abstract: Bacteria with improved survival under toxic and oxidative stress and methods of using the same for bioremediation are described. Many bacteria such as Escherichia coli have been found to naturally reduce toxic pollutants into a less toxic form, such as by reducing Chromium (VI) to Chromium (III). Reducing such toxins generates damaging reactive oxygen species, so it is important to find a defense for these bacteria against the associated oxidative stress. Trehalose is a small biomolecule that has been shown to protect bacteria from various types of stress by accumulating within the cells. The present invention is directed to bacteria genetically modified to overexpress trehalose biosynthesis genes. The bacteria demonstrate improved viability when challenged with toxins and oxidative stress. The present invention provides inexpensive and beneficial bacteria and methods for environmental remediation.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: July 9, 2013
    Inventors: Peter J. Woodruff, Tamlyn M. Frederick
  • Patent number: 8460648
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: June 11, 2013
    Inventor: Thomas Julius Borody
  • Patent number: 8440203
    Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: May 14, 2013
    Assignee: Intervet Inc.
    Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
  • Patent number: 8425917
    Abstract: The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: April 23, 2013
    Assignee: Hunter Immunology Ltd
    Inventor: Timothy Raymond Hirst
  • Patent number: 8425916
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: April 23, 2013
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 8357372
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: January 22, 2013
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Patent number: 8357486
    Abstract: Described herein are methods for detecting a bacteria in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using bacteria. The methods can be used in conjunction with methods for treating a disease, disorder or condition. Such sites, diseases and disorders include sites of cellular proliferation, such as tumors, tumor tissues, metastases, areas of inflammation, immunoprivileged sites or tissues, wounds and infections. Further described are bacteria for use in the methods and compositions, combinations and kits, including diagnostic and pharmaceutical compositions, containing a bacterium. Bacteria described herein include those that bind, sequester or accumulate radiolabeled compounds by expression of an endogenous gene product that binds to the radiolabeled compound. Additional imaging and therapeutic agents and methods also are described.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: January 22, 2013
    Assignee: Genelux Corporation
    Inventors: Jochen Harald Stritzker, Aladar A. Szalay
  • Patent number: 8343509
    Abstract: Described herein are methods for detecting a bacteria in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using bacteria. The methods can be used in conjunction with methods for treating a disease, disorder or condition. Such sites, diseases and disorders include sites of cellular proliferation, such as tumors, tumor tissues, metastases, areas of inflammation, immunoprivileged sites or tissues, wounds and infections. Further described are bacteria for use in the methods and compositions, combinations and kits, including diagnostic and pharmaceutical compositions, containing a bacterium. Bacteria described herein include those that bind, sequester or accumulate radiolabeled compounds by expression of an endogenous gene product that binds to the radiolabeled compound. Additional imaging and therapeutic agents and methods also are described.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: January 1, 2013
    Assignee: Genelux Corporation
    Inventors: Jochen Harald Stritzker, Aladar A. Szalay
  • Patent number: 8323668
    Abstract: The present invention describes a novel mechanism of adhesion by flagellated Gram-negative bacteria such as enterotoxigenic Escherichia coli (ETEC), where the bacteria secretes a protein, EtpA which binds to the conserved region of the flagellin protein located at the tip of the flagella. The present invention also discloses that EtpA-mediated interaction and intestinal colonization require interaction with flagellin. Also disclosed herein is a vaccine composition that can be used for either active or passive immunization of mammals for the prevention or treatment of infections caused by flagellated Gram-negative bacteria.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: December 4, 2012
    Assignee: The University of Tennessee Research Foundation
    Inventor: James M. Fleckenstein
  • Patent number: 8318148
    Abstract: The invention provides strains of bacteria, especially enterotoxigenic E. coli, attenuated by mutations in the genes encoding enterotoxins (LT, ST, EAST1) and optionally further attenuated by deletion of additional chromosomal genes. In addition the invention provides strains of attenuated bacteria expressing immunogenic but non-toxic variants of one or more of these enterotoxins. These bacteria are useful as a vaccine against diarrhoeal disease.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: November 27, 2012
    Assignee: Acambis Research Limited
    Inventors: Arthur Keith Turner, Judith Greenwood, Jonathan Clive Stephens, Juliet Claire Beavis, Michael James Darsley
  • Patent number: 8282941
    Abstract: The present invention provides compositions including siderophore receptor polypeptides from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: October 9, 2012
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 8277821
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: October 2, 2012
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 8263561
    Abstract: The present invention relates to a therapeutic composition comprising a pharmaceutically active agent and a diarrheagenic agent, wherein the diarrheagenic agent induces diarrhea to reduce the harmful or undesired side effects of the pharmaceutically active agent when the pharmaceutically active agent is ingested at a dose higher than the prescribed dose.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: September 11, 2012
    Assignee: Amana Pharmaceuticals Corp.
    Inventor: Mohammed Saeed
  • Publication number: 20120213821
    Abstract: The invention concerns a novel method for extracting endotoxins from bacteria, and the use of said method for preparing compositions comprising endotoxins or derivatives thereof designed for human or animal use (scientific, medical usage).
    Type: Application
    Filed: February 8, 2012
    Publication date: August 23, 2012
    Applicant: UNIVERSITE PARIS SUD XI
    Inventor: Martine CAROFF
  • Patent number: 8246945
    Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: August 21, 2012
    Assignees: University of Arkansas, Mount Sinai School of Medicine of New York University, Allertein Therapeutics, LLC
    Inventors: Michael J. Caplan, H. Kim Bottomly, Howard B. Sosin, A. Wesley Burks, Hugh A. Sampson
  • Patent number: 8241608
    Abstract: A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: August 14, 2012
    Assignees: Development Center for Biotechnology, DCB-USA LLC
    Inventors: Yu-Shen Hsu, Jiu-Yao Wang
  • Publication number: 20120201853
    Abstract: Provided is a use of a holotoxin to reduce endoplasmic reticulum-associated degradation (ERAD) of misfolded or abnormally folded proteins The holotoxin can thus be used in a method to treat diseases related to ERAD Examples of misfolded proteins that are degraded in the ER include the cystic fibrosis transmembrane conductance regulator (CFTR) delta F508 mutant protein, a misfolded mutant (G268V) of multi-drug resistance 1 (MDR1), and the glucocerebrosidase (GCC) enzyme in Gaucher's disease cells Examples of suitable holotoxins include ricin, shiga toxin, exotoxin A, plasmid-encoded toxin, cholera toxin, and verotoxin 1 (VT1) VT1 is also known as verotoxin A, shiga-like toxin 1, shiga-like toxin 1, or shiga toxin in type 1 A non-toxic inactive VT1 can also be used wherein crucial residues of the A subunit active site are mutated, for example, the mutations Y77S and E167Q
    Type: Application
    Filed: August 27, 2010
    Publication date: August 9, 2012
    Inventor: Clifford Lingwood
  • Patent number: 8236522
    Abstract: The present invention relates to an extract from bacterial strains useful as a treatment for disorders such as digestive or urinary tract disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: August 7, 2012
    Assignee: OM Pharma
    Inventors: Jacques Alain Bauer, Marco Salvagni, Jean-Pierre Leon Vigroux, Laetitia Chalvet, Carlo Chiavaroli
  • Patent number: 8178340
    Abstract: The present invention relates to human specific Escherichia coli strains.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: May 15, 2012
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Olivier Clermont, Erick Denamur, Tony Le Gall, Olivier Tenaillon
  • Patent number: 8133496
    Abstract: The present invention relates to methods and compositions for treating urinary tract infections. In particular, the present invention relates to vaccines and immune modulators for treating urinary tract infections.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: March 13, 2012
    Assignee: The Regents of the University of Michigan
    Inventor: Harry L. T. Mobley
  • Patent number: 8110197
    Abstract: This invention relates to a mutant E. coli heat-labile enterotoxin (LT) subunit A that can be used as an adjuvant. This subunit A mutant contains an amino acid substitution at a position corresponding to position 61 of a wild-type LT. An LT containing this mutated subunit A exhibits reduced toxicity compared to its wild type counterpart.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: February 7, 2012
    Assignee: Development Center for Biotechnology
    Inventors: Yu-Shen Hsu, Young-Sun Lin, Ta-Tung Yuan
  • Patent number: 8088394
    Abstract: This invention relates to a mutant E. coli heat-labile enterotoxin (LT) subunit A that can be used as an adjuvant. This subunit A mutant contains an amino acid substitution at a position corresponding to position 61 of a wild-type LT. An LT containing this mutated subunit A exhibits reduced toxicity compared to its wild type counterpart.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: January 3, 2012
    Assignee: Development Center for Biotechnology
    Inventors: Yu-Shen Hsu, Young-Sun Lin, Ta-Tung Yuan
  • Patent number: 8062644
    Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: November 22, 2011
    Assignee: Novartis Vaccines & Diagnostics SRL.
    Inventors: Mariagrazia Pizza, Laura Serino, Francesco Berlanda Scorza, Danilo Gomes Moriel, Maria Rita Fontana
  • Publication number: 20110280908
    Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.
    Type: Application
    Filed: April 15, 2011
    Publication date: November 17, 2011
    Applicants: Services, National Institutes of Health, Office of Technology Transfer
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
  • Patent number: 8057805
    Abstract: A novel Edwardsiella ictaluri E-ict-VL33 strain, a vaccine derived from the novel Edwardsiella ictaluri E-ict-VL33 strain, especially in immersion form and oral form, and a method for protecting fishes from the infection of Edwardsiella ictaluri, especially catfish, the method including a primary immersion immunization using immersion vaccine, and after an appropriate period, boosting by oral vaccination, resulting in a strong and long-lasting immunity for fishes.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: November 15, 2011
    Assignee: Schweitzer Biotech Company Ltd.
    Inventors: Tsun-Yung Kuo, Hsu Chung Gabriel Chen
  • Publication number: 20110236424
    Abstract: A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.
    Type: Application
    Filed: March 23, 2010
    Publication date: September 29, 2011
    Applicants: Development Center for Biotechnology, DCB-USA LLC
    Inventors: Yu-Shen Hsu, Jiu-Yao Wang
  • Patent number: 7988978
    Abstract: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field strains of E. coli, Pseudomona aeruginosa, Aerobacter aerogenes, Salmonella enteritidis, Salmonella typhimurium, Salmonella agona, and Salmonella Kentucky. The antigen composition can be used alone or in combination with a Marek's Disease vaccine to reduce shedding of E. coli and/or Salmonella bacteria.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: August 2, 2011
    Assignee: Nutrional Health Institute Laboratories, LLC
    Inventor: Konky Sotomayor
  • Publication number: 20110150923
    Abstract: The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and/or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Th1/Th2 bias of the responses.
    Type: Application
    Filed: February 28, 2011
    Publication date: June 23, 2011
    Inventors: Giuseppe Del Giudice, Barbara Baudner, Derek O'Hagan
  • Patent number: 7951361
    Abstract: A bacterial cell which expresses three or more coli surface (CS) antigens and methods of making such a cell. The cell is useful in making vaccines against diarrhea.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: May 31, 2011
    Assignee: Acambis Research Limited
    Inventors: Arthur Keith Turner, Judith Greenwood, Jonathan Clive Stephens, Juliet Claire Beavis, Michael James Darsley
  • Patent number: 7943151
    Abstract: The present invention provides compositions including siderophore receptor polypeptides from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions, including inducing the production of antibody in an animal.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: May 17, 2011
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 7943122
    Abstract: The invention provides strains of bacteria, especially enterotoxigenic E. coli, attenuated by mutations in the genes encoding enterotoxins (LT, ST, EAST1) and optionally further attenuated by deletion of additional chromosomal genes. In addition the invention provides strains of attenuated bacteria expressing immunogenic but non-toxic variants of one or more of these enterotoxins. These bacteria are useful as a vaccine against diarrhoeal disease.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: May 17, 2011
    Assignee: Acambis Research Limited
    Inventors: Arthur Keith Turner, Judith Greenwood, Jonathan Clive Stephens, Juliet Claire Beavis, Michael James Darsley
  • Patent number: 7943150
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions, including inducing the production of antibody in an animal.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: May 17, 2011
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 7923001
    Abstract: The present invention relates to methods and compositions for treating urinary tract infections. In particular, the present invention relates to vaccines and immune modulators for treating urinary tract infections.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: April 12, 2011
    Assignee: The Regents of the University of Michigan
    Inventor: Harry L. T. Mobley
  • Patent number: 7914791
    Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: March 29, 2011
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Timothy Raymond Hirst, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
  • Patent number: 7883709
    Abstract: This invention relates to the stabilization of a bacterial ADP-ribosylating exotoxin class protein (bARE), a method for analysing a bARE class protein, a method for the stabilization of the bARE class bacterial protein, compositions comprising a stabilized bARE protein, compositions comprising a substantially integral bARE class protein and immunogenic composition formulations incorporating same.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: February 8, 2011
    Assignee: Novartis AG
    Inventors: Claudia Magagnoli, Maurizio Morandi